ABC of antithrombotic therapy: Bleeding risks of antithrombotic therapy

British Medical Journal

Volumn 325, Issue 7368, 2002, Pages 828-831

  Fitzmaurice, David A ^a   Blann, Andrew D ^b   Lip, Gregory Y H ^b  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 10A INHIBITOR; BLOOD CLOTTING FACTOR 9; FRESH FROZEN PLASMA; PROTHROMBIN; RECOMBINANT BLOOD CLOTTING FACTOR 7A; VITAMIN K GROUP; WARFARIN; ANTITHROMBOCYTIC AGENT; FIBRINOLYTIC AGENT;

AGED; ANTICOAGULANT THERAPY; BLEEDING; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG INDUCED DISEASE; GASTROINTESTINAL HEMORRHAGE; GERIATRIC PATIENT; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HEMATOLOGICAL PARAMETERS; HEMOPTYSIS; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MENORRHAGIA; META ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; STROKE; THROMBOEMBOLISM; CHEMICALLY INDUCED DISORDER; THROMBOSIS;

ANTICOAGULANTS; ASPIRIN; FIBRINOLYTIC AGENTS; HEMORRHAGE; HUMANS; PLATELET AGGREGATION INHIBITORS; RISK FACTORS; THROMBOSIS; WARFARIN;

EID: 0037068999     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.325.7368.828     Document Type: Review

References (0)